Recently, the application of MALDI-MSI to imaging small metabolites has received increasing interest. MSI of metabolites can provide unqiue insight into the metabolic alterations caused by many diseases and metabolic perturbations such as ischemic stroke , migraine , kidney repair as well as metabolism in non-mammlian samples such as plants. Metabolite imaging using MSI is also a very promising appoach for mapping metabolic changes within tumours where the metabolic environment is significantly altered, for example, by the Warburg effect. Examples of MALDI-MSI of metabolite distributions in cancer include glioblastoma , thyroid cancer subtypes , pancreatic ductul adenocarcinoma and breast cancer brain metastasis. MALDI-MSI of metabolites is typically performed in the negative-ion mode using matrices 9-aminoacridine (9-AA), diaminonaphthalene (DAN) and N- (1-naphthyl) ethylenediamine dihydrochloride (NEDC). However, analyte coverage is often limited by varied and often low ionisation efficiencies of analytes (as low as 10-9), an effect further compounded by the complex nature of biological samples leading to ion suppression effects.